Current concepts in breast cancer chemoprevention

Polskie Archiwum Medycyny Wewnetrznej

Volumn 124, Issue 4, 2014, Pages 191-199

  Chlebowski, Rowan T ^a  

^a UCLA MEDICAL CENTER   (United States)

Author keywords

Aromatase inhibitors; Breast cancer; Chemoprevention; Raloxifene; Tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ESTROGEN; EXEMESTANE; GESTAGEN; LASOFOXIFENE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; ANDROSTANE DERIVATIVE; ANTIESTROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; NITRILE; TRIAZOLE DERIVATIVE;

BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; ENDOMETRIUM CANCER; HEALTH; HUMAN; MENOPAUSAL SYNDROME; PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE; REVIEW; BREAST NEOPLASMS; FEMALE; INCIDENCE; PREMENOPAUSE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ANDROSTADIENES; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOPREVENTION; ESTROGEN ANTAGONISTS; ESTROGENS; FEMALE; HUMANS; INCIDENCE; NITRILES; POSTMENOPAUSE; PREMENOPAUSE; PROSPECTIVE STUDIES; RALOXIFENE HYDROCHLORIDE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TREATMENT OUTCOME; TRIAZOLES;

EID: 84901461395     PISSN: 00323772     EISSN: 18979483     Source Type: Journal    
DOI: 10.20452/pamw.2190     Document Type: Review

References (56)

1. Visvanathan K, Chlebowski RT, Hurley P, et al. American Society of Clinical Oncology 2008 clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibitor for breast cancer risk reduction. J Clin Oncol. 2009; 27: 3235-3258.
2. Santen RJ, Song Y, Yue W, et al. Effects of menopausal hormonal therapy on occult breast tumors. J Steroid Biochem Mol Biol. 2013; 137: 150-156.
3. Rossouw JE, Anderson GL, Prentice RL, et al. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288: 321-333. (Pubitemid 34761611)
4. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998; 351: 1451-1467.
5. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998; 90: 1371-1388. (Pubitemid 28439961)
6. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005; 97: 1652-1662. (Pubitemid 41672231)
7. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet. 1998; 352: 98-101. (Pubitemid 28321321)
8. Powles TJ, Ashley S, Tidy A, et al. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst. 2007; 99: 283-290. (Pubitemid 47073491)
9. Cuzick J, Forbes J, Edwards R, et al.; for the IBIS investigators. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet. 2002; 360: 817-824. (Pubitemid 35257944)
10. Cuzick J, Forbes JF, Sestak I, et al. Long-term results of tamoxifen prophylaxis for breast cancer - 96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst. 2007; 99: 272-282. (Pubitemid 47073490)
11. Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet. 1998; 352: 93-97. (Pubitemid 28321320)
12. Veronesi U, Maisonneuve P, Rotmensz N, et al. Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst. 2007; 99: 727-737. (Pubitemid 47073533)
13. Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat. 2001; 65: 125-134. (Pubitemid 32193616)
14. Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista; breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst. 2004; 96: 1751-1761. (Pubitemid 39654569)
15. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006; 355: 125-137. (Pubitemid 44050394)
16. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. JAMA. 2006; 295: 2727-2741.
17. Vogel VG, Costantino JP, Wickerham DL, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev Res. 2010; 3: 696-706.
18. Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003; 361: 296-300. (Pubitemid 36126189)
19. Cuzick J, Sestak I, Bonanni B, et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet. 2013; 381: 1827-1834.
20. Waters EA, McNeel TS, Stevens WM, Freedman AN. Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010. Breast Cancer Res Treat. 2012; 134: 875-880.
21. Freedman AN, Yu B, Gail MH, et al. Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifene for women age 50 years or older. J Clin Oncol. 2011; 29: 2327-2333.
22. LaCroix AZ, Powles T, Osborne CK, et al. Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. J Natl Cancer Inst. 2010; 102: 1706-1715.
23. Cummings SR, Ensrud K, Delmass PD, et al. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med. 2010; 362: 686-696.
24. Schmidt C. Third-generation SERMs may face uphill battle. JNCI J Natl Cancer Inst. 2010; 102: 1690-1692.
25. Cummings SR, McClung M, Reginster JY, et al. Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women. J Bone Miner Res. 2011; 26: 397-404.
26. Powles TJ, Diem SJ, Fabian CJ, et al. Breast cancer incidence in post-menopausal women with osteoporosis or low bone mass using arzoxifene. Breast Cancer Res Treat. 2012; 134: 299-306.
27. Anderson GL, Limacher M, Assaf R, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA. 2004; 291: 1701-1712. (Pubitemid 38489892)
28. Chlebowski RT, Anderson GL. Changing concepts: menopausal hormone therapy and breast cancer. J Natl Cancer Inst. 2012; 104: 517-527.
29. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended post-stopping phases of the Women's Health Initiative randomized trials. JAMA. 2013; 310: 1353-1368.
30. Chlebowski RT, Hendrix SL, Langer RD, et al. Estrogen plus progestin influence on breast cancer and mammography in healthy postmenopausal women: The Women's Health Initiative randomized trial. JAMA. 2003; 289: 3243-3253. (Pubitemid 37430077)
31. Chlebowski RT, Anderson GL, Gass M, et al. Influence of estrogen plus progestin on breast cancer incidence and morality. JAMA. 2010: 304: 1684-1692.
32. Chlebowski RT, Anderson G, Pettinger M, et al. Estrogen plus progestin and breast cancer detection with mammography and breast biopsy. JAMA. 2008; 168: 382-391.
33. Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography in postmenopausal women with hysterectomy: The Women's Health Initiative randomized trial. JAMA. 2006; 242: 1048-1063.
34. Anderson GL, Chlebowski RT, Aragaki A, et al. Oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy extended follow-up of the Women's Health Initiative randomized trial. Lancet Oncol. 2012; 13: 476-486.
35. Hersh AL, Stefanick ML, Stafford RS. National use of menopausal hormone therapy: annual trends and response to recent evidence. JAMA. 2004; 29: 47-53. (Pubitemid 38040534)
36. Zbuk K, Anand SS. Declining incidence of breast cancer after decreased use of hormone-replacement therapy: magnitude and time lags in different countries. J Epidemiol Community Health. 2012; 66: 1-7.
37. Clarke CA, Glaser SL, Uratsu CS, et al. Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence. J Clin Oncol. 2006; 24: e49-e50.
38. Ravdin PM, Cronin KA, Howlander N, et al. The decrease in breast cancer incidence in 2003 in the United States. N Engl J Med. 2007; 356: 1670-1674. (Pubitemid 46631679)
39. Chlebowski RT, Kuller L, Prentice RL, et al. Breast cancer after estrogen plus progestin use in postmenopausal women. N Engl J Med. 2009; 360: 573-587.
40. Goss PE, Ingle JN, Ales-Martin LJ, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011; 364: 2381-2391.
41. Solomon SD, McMurray JJV, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005; 352: 1071-1080. (Pubitemid 40365348)
42. Maunsell E, Goss PE, Chlebowski RT, et al. Quality of life in MAP.3: a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer. J Clin Oncol. 2014. [In press].
43. Ingle JN, Tu D, Pater JL, et al. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Res Treat. 2006; 99: 295-300. (Pubitemid 44337921)
44. Cuzick J, Sestak I, Forbes JF, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet. 2014; 383: 1041-1048.
45. Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010; 28: 509-518.
46. Goodwin PJ, Stambolic V. Obesity and insulin resistance in breast cancer - chemoprevention strategies with a focus on metformin. Breast. 2011; Suppl 3: S31-5.
47. Chlebowski RT, McTiernan A, Wactawski-Wende J, et al. Diabetes, metformin and breast cancer in postmenopausal women. J Clin Oncol. 2012. doi: 10.1200/JCO.2011.39.7505.
48. Baselga J, Cortes J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012; 366: 109-119.
49. Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012; 13: 25-32.
50. A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer. ClinicalTrials.gov. Accessed February 26, 2014.
51. Wacholder S, Hartge P, Prentice R, et al. Performance of common genetic variants in breast cancer risk models. N Engl J Med. 2010; 362: 986-993.
52. Brentnall AR, Evans DG, Cuzick J. Value of phenotypic and single-nucleotide polymorphism panel markers in predicting the risk of breast cancer. J Genet Syndr Gene Ther. 2013; 4: 202-203.
53. Ellis MJ, Perou CM. The genomic landscape of breast cancer as a therapeutic roadmap. Cancer Discov. 2013; 3: 27-34.
54. Finn RS, Crown JP, Lang I, et al. Results of a randomized phase 2 study of PD 0.2991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2 - advanced breast cancer (BC). Cancer Res. 2012; 72: S1-S6.
55. Chlebowski RT. Strategies to overcome endocrine therapy resistance in hormone receptor-positive advanced breast cancer. Clin Investig. 2014. [In press].
56. Baselga J, Compone M, Piccart M, et al. Everolimus in postmenopausal hormone receptor-positive advanced breast cancer. N Engl J Med. 2012; 366: 520-529.